Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

Santi Suryani, Lauryn S. Bracken, Richard C. Harvey, Keith C.S. Sia, Hernan Carol, I. Ming Chen, Kathryn Evans, Philipp A. Dietrich, Kathryn G. Roberts, Raushan T. Kurmasheva, Catherine A. Billups, Charles G. Mullighan, Cheryl L. Willman, Mignon L. Loh, Stephen P. Hunger, Peter J Houghton, Malcolm A. Smith, Richard B. Lock

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAK). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor AZD1480, both as a single agent and in combination with the MEK inhibitor selumetinib, against JAK-mutated patient-derived xenografts. Patient-derived xenografts were established in immunodeficient mice from bone marrow or peripheral blood biopsy specimens, and their gene expression profiles compared with the original patient biopsies by microarray analysis. JAK/STAT and MAPK signaling pathways, and the inhibitory effects of targeted drugs, were interrogated by immunoblotting of phosphoproteins. The antileukemic effects of AZD1480 and selumetinib, alone and in combination, were tested against JAK-mutated ALL xenografts both in vitro and in vivo. Xenografts accurately represented the primary disease as determined by gene expression profiling. Cellular phosphoprotein analysis demonstrated that JAK-mutated xenografts exhibited heightened activation status of JAK/STAT and MAPK signaling pathways compared with typical B-cell precursor ALL xenografts, which were inhibited by AZD1480 exposure. However, AZD1480 exhibited modest single-agent in vivo efficacy against JAK-mutated xenografts. Combining AZD1480 with selumetinib resulted in profound synergistic in vitro cell killing, although these results were not translated in vivo despite evidence of target inhibition. Despite validation of target inhibition and the demonstration of profound in vitro synergy between AZD1480 and selumetinib, it is likely that prolonged target inhibition is required to achieve in vivo therapeutic enhancement between JAK and MEK inhibitors in the treatment of JAK-mutated ALL.

Original languageEnglish (US)
Pages (from-to)364-374
Number of pages11
JournalMolecular Cancer Therapeutics
Volume14
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Janus Kinases
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Heterografts
Phosphoproteins
Mitogen-Activated Protein Kinase Kinases
Biopsy
AZD 1480
In Vitro Techniques
B-Lymphoid Precursor Cells
Gene Expression Profiling
Microarray Analysis
Transcriptome
Immunoblotting
Bone Marrow
Genome
Pediatrics
Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. / Suryani, Santi; Bracken, Lauryn S.; Harvey, Richard C.; Sia, Keith C.S.; Carol, Hernan; Chen, I. Ming; Evans, Kathryn; Dietrich, Philipp A.; Roberts, Kathryn G.; Kurmasheva, Raushan T.; Billups, Catherine A.; Mullighan, Charles G.; Willman, Cheryl L.; Loh, Mignon L.; Hunger, Stephen P.; Houghton, Peter J; Smith, Malcolm A.; Lock, Richard B.

In: Molecular Cancer Therapeutics, Vol. 14, No. 2, 01.02.2015, p. 364-374.

Research output: Contribution to journalArticle

Suryani, S, Bracken, LS, Harvey, RC, Sia, KCS, Carol, H, Chen, IM, Evans, K, Dietrich, PA, Roberts, KG, Kurmasheva, RT, Billups, CA, Mullighan, CG, Willman, CL, Loh, ML, Hunger, SP, Houghton, PJ, Smith, MA & Lock, RB 2015, 'Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia', Molecular Cancer Therapeutics, vol. 14, no. 2, pp. 364-374. https://doi.org/10.1158/1535-7163.MCT-14-0647
Suryani, Santi ; Bracken, Lauryn S. ; Harvey, Richard C. ; Sia, Keith C.S. ; Carol, Hernan ; Chen, I. Ming ; Evans, Kathryn ; Dietrich, Philipp A. ; Roberts, Kathryn G. ; Kurmasheva, Raushan T. ; Billups, Catherine A. ; Mullighan, Charles G. ; Willman, Cheryl L. ; Loh, Mignon L. ; Hunger, Stephen P. ; Houghton, Peter J ; Smith, Malcolm A. ; Lock, Richard B. / Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. In: Molecular Cancer Therapeutics. 2015 ; Vol. 14, No. 2. pp. 364-374.
@article{dc83b4595ea24012bc6be312066e2219,
title = "Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia",
abstract = "Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAK). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor AZD1480, both as a single agent and in combination with the MEK inhibitor selumetinib, against JAK-mutated patient-derived xenografts. Patient-derived xenografts were established in immunodeficient mice from bone marrow or peripheral blood biopsy specimens, and their gene expression profiles compared with the original patient biopsies by microarray analysis. JAK/STAT and MAPK signaling pathways, and the inhibitory effects of targeted drugs, were interrogated by immunoblotting of phosphoproteins. The antileukemic effects of AZD1480 and selumetinib, alone and in combination, were tested against JAK-mutated ALL xenografts both in vitro and in vivo. Xenografts accurately represented the primary disease as determined by gene expression profiling. Cellular phosphoprotein analysis demonstrated that JAK-mutated xenografts exhibited heightened activation status of JAK/STAT and MAPK signaling pathways compared with typical B-cell precursor ALL xenografts, which were inhibited by AZD1480 exposure. However, AZD1480 exhibited modest single-agent in vivo efficacy against JAK-mutated xenografts. Combining AZD1480 with selumetinib resulted in profound synergistic in vitro cell killing, although these results were not translated in vivo despite evidence of target inhibition. Despite validation of target inhibition and the demonstration of profound in vitro synergy between AZD1480 and selumetinib, it is likely that prolonged target inhibition is required to achieve in vivo therapeutic enhancement between JAK and MEK inhibitors in the treatment of JAK-mutated ALL.",
author = "Santi Suryani and Bracken, {Lauryn S.} and Harvey, {Richard C.} and Sia, {Keith C.S.} and Hernan Carol and Chen, {I. Ming} and Kathryn Evans and Dietrich, {Philipp A.} and Roberts, {Kathryn G.} and Kurmasheva, {Raushan T.} and Billups, {Catherine A.} and Mullighan, {Charles G.} and Willman, {Cheryl L.} and Loh, {Mignon L.} and Hunger, {Stephen P.} and Houghton, {Peter J} and Smith, {Malcolm A.} and Lock, {Richard B.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-14-0647",
language = "English (US)",
volume = "14",
pages = "364--374",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

AU - Suryani, Santi

AU - Bracken, Lauryn S.

AU - Harvey, Richard C.

AU - Sia, Keith C.S.

AU - Carol, Hernan

AU - Chen, I. Ming

AU - Evans, Kathryn

AU - Dietrich, Philipp A.

AU - Roberts, Kathryn G.

AU - Kurmasheva, Raushan T.

AU - Billups, Catherine A.

AU - Mullighan, Charles G.

AU - Willman, Cheryl L.

AU - Loh, Mignon L.

AU - Hunger, Stephen P.

AU - Houghton, Peter J

AU - Smith, Malcolm A.

AU - Lock, Richard B.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAK). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor AZD1480, both as a single agent and in combination with the MEK inhibitor selumetinib, against JAK-mutated patient-derived xenografts. Patient-derived xenografts were established in immunodeficient mice from bone marrow or peripheral blood biopsy specimens, and their gene expression profiles compared with the original patient biopsies by microarray analysis. JAK/STAT and MAPK signaling pathways, and the inhibitory effects of targeted drugs, were interrogated by immunoblotting of phosphoproteins. The antileukemic effects of AZD1480 and selumetinib, alone and in combination, were tested against JAK-mutated ALL xenografts both in vitro and in vivo. Xenografts accurately represented the primary disease as determined by gene expression profiling. Cellular phosphoprotein analysis demonstrated that JAK-mutated xenografts exhibited heightened activation status of JAK/STAT and MAPK signaling pathways compared with typical B-cell precursor ALL xenografts, which were inhibited by AZD1480 exposure. However, AZD1480 exhibited modest single-agent in vivo efficacy against JAK-mutated xenografts. Combining AZD1480 with selumetinib resulted in profound synergistic in vitro cell killing, although these results were not translated in vivo despite evidence of target inhibition. Despite validation of target inhibition and the demonstration of profound in vitro synergy between AZD1480 and selumetinib, it is likely that prolonged target inhibition is required to achieve in vivo therapeutic enhancement between JAK and MEK inhibitors in the treatment of JAK-mutated ALL.

AB - Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAK). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor AZD1480, both as a single agent and in combination with the MEK inhibitor selumetinib, against JAK-mutated patient-derived xenografts. Patient-derived xenografts were established in immunodeficient mice from bone marrow or peripheral blood biopsy specimens, and their gene expression profiles compared with the original patient biopsies by microarray analysis. JAK/STAT and MAPK signaling pathways, and the inhibitory effects of targeted drugs, were interrogated by immunoblotting of phosphoproteins. The antileukemic effects of AZD1480 and selumetinib, alone and in combination, were tested against JAK-mutated ALL xenografts both in vitro and in vivo. Xenografts accurately represented the primary disease as determined by gene expression profiling. Cellular phosphoprotein analysis demonstrated that JAK-mutated xenografts exhibited heightened activation status of JAK/STAT and MAPK signaling pathways compared with typical B-cell precursor ALL xenografts, which were inhibited by AZD1480 exposure. However, AZD1480 exhibited modest single-agent in vivo efficacy against JAK-mutated xenografts. Combining AZD1480 with selumetinib resulted in profound synergistic in vitro cell killing, although these results were not translated in vivo despite evidence of target inhibition. Despite validation of target inhibition and the demonstration of profound in vitro synergy between AZD1480 and selumetinib, it is likely that prolonged target inhibition is required to achieve in vivo therapeutic enhancement between JAK and MEK inhibitors in the treatment of JAK-mutated ALL.

UR - http://www.scopus.com/inward/record.url?scp=84923381331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923381331&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-14-0647

DO - 10.1158/1535-7163.MCT-14-0647

M3 - Article

VL - 14

SP - 364

EP - 374

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -